PRELIMINARY CLINICAL DATA FROM A PHASE 1B STUDY OF MAVORIXAFOR AND IBRUTINIB IN PATIENTS WITH WALDENSTRöM MACROGLOBULINEMIA WITH MYD88 AND CXCR4 MUTATIONS. (17th June 2021)

• Record Type: Journal Article
• Authors: Treon, S.; Buske, C.; Thomas, S.; Branagan, A.; Dimopoulos, M.; Castillo, J. J.; Garzon, F.; Tang, W.; Ronan, R.; Seyffert, S.; Garg, V.; Ali, S.; Taveras, A.; Badarau, A.; Zmajkovicova, K.; Maier, S.; Maierhofer, B.; Matous, J.
• Is Part Of: Hematological oncology. Volume 39(2021)Supplement 2
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-06-17
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.86_2881
• Languages: English
• ISSNs: 0278-0232